Results 171 to 180 of about 589,195 (286)

Functional Impact of Structural Damage in Psoriatic Arthritis: Insights from a Prospective Cohort Study

Arthritis &Rheumatology, Accepted Article.
Objective To examine the association between radiographic structural damage and physical function (PF) in psoriatic arthritis (PsA). Methods Data were analyzed from a large longitudinal PsA cohort. PF was measured using the Health Assessment Questionnaire (HAQ, 0‐3) and Short Form‐36 PF subscale (SF‐36, 0‐100); radiographic joint damage using modified ...
Pankti Mehta, Shangyi Gao, Virginia Carrizo Abarza, Fadi Kharouf, Daniel Pereira, Richard J. Cook, Dafna D. Gladman, Vinod Chandran, Denis Poddubnyy   +8 more
wiley   +1 more source

Mechanistic Insights from Human Studies in Axial Spondyloarthritis: A T Cell Story. [PDF]

Curr Rheumatol Rep
Um J, Paley MA.
europepmc   +1 more source

PD-1 blockade does not enhance alloimmunization after allogeneic dendritic cell vaccination in cancer patients. [PDF]

Front Immunol
Planel S, Vayssière G, Maggipinto G, Leplus E, Laulagnier K, Renard F, Myster F, Gerard M, Demedts I, Cuppens K, Pons-Tostivint E, Wauters E, Borm FJ, Sibille A, Colinet B, Pérol M, Theelen WSME, Biesma B, Van De Kerkhove C, Buchmeier E, Althoff FC, Derijcke S, Moro-Sibilot D, Cantero F, Chaperot L, Saas P, Skrzypski M, Vansteenkiste J, Plumas J.   +28 more
europepmc   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Effect of carbamazepine on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting Chimera estrogen receptor degrader, in healthy adults

British Journal of Clinical Pharmacology, EarlyView.
Aim To evaluate the effects of carbamazepine, a strong cytochrome P450 (CYP)3A4 inducer, on the pharmacokinetics and safety of vepdegestrant, a PROteolysis TArgeting Chimera estrogen receptor degrader. Methods This was a phase 1, open‐label, fixed‐sequence, two‐period study in healthy adult participants.
Hechuan Wang, Jennifer A. Winton, Kyle T. Matschke, Alexandre Stouffs, Kimberly C. Lee, Yuanyuan Zhang, Wenlian Qiao, Weiwei Tan   +7 more
wiley   +1 more source

Immunogenicity of neoantigens from hepatocellular carcinoma patients treated with a combined radioimmunotherapy. [PDF]

Oncoimmunology
Aparicio B, Silva L, Ruiz M, Llópiz D, Repáraz D, Theunissen P, Tamayo I, Egea J, Igea A, Smerdou C, Peñas M, Perpiñá C, Matilla A, Varela M, Reig M, de la Torre-Alaez M, Argemí J, Sangro B, Hervás-Stubbs S, Sarobe P.   +19 more
europepmc   +1 more source

APOE genotype and the effect of statins on lipid outcomes: A meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aim APOE genotype may affect statin therapy response. We conducted a meta‐analysis to update and quantify this association across various outcomes. Methods We searched seven databases (MEDLINE, Scopus, Web of Science, the Cochrane Library, APA PsycINFO, CINAHL Plus and ClinicalTrials.gov) on 9 May 2024.
Innocent G. Asiimwe, Tsegay Gebru, Andrea L. Jorgensen, Munir Pirmohamed, on behalf of the Multimorbidity Mechanism and Therapeutics Research Collaborative   +4 more
wiley   +1 more source

Non-HLA antibody trajectories may predict kidney transplant outcomes. [PDF]

Front Immunol
Rajalingam R, Sigdel TK, Maruthamuthu S, Raghav PK, Laszik ZG, Da Gente G, Kong D, Shoji J, Ray B.   +8 more
europepmc   +1 more source

Consistency and clarity of pharmacogenomic guidance in UK medicine patient information leaflets: A cross‐sectional analysis

British Journal of Clinical Pharmacology, EarlyView.
Pharmacogenomic (PGx) information has the potential to support the safe and effective use of medicines, yet there is uncertainty about how this information can be best communicated to patients. Summaries of product characteristics (SmPCs) and patient information leaflets (PILs) for all UK‐approved medicines with strong evidence supporting a PGx ...
Parth Narlawar, Chloe Ratcliffe, Videha Sharma, William G. Newman, Munir Pirmohamed, John McDermott   +5 more
wiley   +1 more source

The non-classical immune checkpoint HLA-G: a regulatory master switch governing tolerance, evasion, and translational frontiers. [PDF]

Front Oncol
Liu H, Li Q, Li J, Xue Y, Xue X, Xu P.
europepmc   +1 more source